BRAF inhibitors are effective only in people with BRAF‐mutated melanoma; BRAF inhibitors combined with MEK inhibitors are the most effective regimen in people with BRAF‐mutated melanoma (at least in terms of progression‐free survival); and anti‐PD1 monoclonal antibodies are the least toxic regimen, but the combination of immune checkpoint inhibitors has highest toxicity. This evidence concerns the gene PDCD1 and melanoma.